Asceneuron Raises $100M for Tau-Targeted Oral Alzheimer’s Treatment Advancing to Phase 2 Trial
Alzheimer’s disease, a neurodegenerative disorder, has been traditionally targeted through treatments focusing on the amyloid protein plaques in the brain, with recent drug approvals such as Eisai’s Leqembi and Eli Lilly’s Kisunla leading the way. These intravenously infused therapies use antibodies to break up amyloid proteins but come with risks such as bleeding and brain […]